Banner image of a Latino male on a green background.

POWERFUL HIV PROTECTION THEY DESERVE

Proven in two large-scale head-to-head trials, HPTN 083 and HPTN 084

See HPTN 083See HPTN 084

Real-world studies

Superior efficacy versus a daily oral PrEP (TRUVADA) demonstrated in two clinical trials1,2*

3x reduction in HIV-1 in HPTN 083 icon. 3x reduction in HIV-1 in HPTN 083 icon.

>3X reduction in HIV-1 incidence in HPTN 083: HR 0.31 (95% CI: 0.16-0.58); P=0.0003

12x reduction in HIV-1 in HPTN 084 icon. 12x reduction in HIV-1 in HPTN 084 icon.

12X reduction in HIV-1 incidence in HPTN 084: HR 0.10 (95% CI: 0.04-0.27); P<0.0001

*HPTN 083 (N=4566) and HPTN 084 (N=3244) were randomized, double-blind, controlled trials evaluating the safety and efficacy of APRETUDE every 2 months vs daily oral TRUVADA for HIV-1 prevention in adults at risk of acquiring HIV-1. The primary endpoint of both studies was the rate of incident HIV-1 infections.

Proven in diverse and inclusive PrEP trials

Banner image of a group of five individuals looking forward.

2 of the largest head-to-head prevention trials conducted through the HIV Prevention Trials Network (HPTN) in cooperation with National Institute of Allergy and Infectious Diseases (NIAID)

Randomized, double-blind, multinational, controlled trials of APRETUDE vs TRUVADA in diverse study populations1,2

STUDY IN CISGENDER MEN AND TRANSGENDER WOMEN

HPTN 083 (N=4566)

See efficacy data

See safety data

Noninferiority trial with the prespecified ability to test for superiority

43 sites around the world

  • US, n=1698 (37%)

DEMOGRAPHICS:

  • 68% were <30 years old
  • 87% were MSM; 13% were TGW
  • 18% in the US were Latinx; 50% in the US were Black/African American

MSM=men who have sex with men; TGW=transgender women.

STUDY IN CISGENDER WOMEN

HPTN 084 (N=3224)

See efficacy data

See safety data

Superiority trial

20 sites around sub-Saharan Africa

DEMOGRAPHICS:

  • 50% were <25 years old
  • 55% had ≥2 sex partners
Banner image of a Caucasian man, a Black man, and a Latina woman on a green background.

APRETUDE has been studied in diverse clinical and real-world populations

Explore studies

PMUS-CBTWCNT250019

References:

  1. Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385(7):595-608. doi:10.1056/NEJMoa2101016

  2. Delany-Moretlwe S, Hughes JP, Bock P, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399(10337):1779-1789. doi:10.1016/S0140-6736(22)00538-4